Drug Therapy of Experimental Tuberculosis (TB): Improved Outcome by Combining SQ109, a New Diamine Antibiotic, with Existing TB Drugs-Reference-Cited by-同舟云学术

Drug Therapy of Experimental Tuberculosis (TB): Improved Outcome by Combining SQ109, a New Diamine Antibiotic, with Existing TB Drugs

Published:2007-04 Issue:4 Volume:51 Page:1563-1565
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Nikonenko Boris V.¹²,Protopopova Marina¹,Samala Rowena¹,Einck Leo¹,Nacy Carol A.¹

Affiliation:

1. Sequella, Inc., Rockville, Maryland 20850

2. Central Research Institute for Tuberculosis, Moscow 107564, Russia

Abstract

ABSTRACT Substitution of the new diamine antibiotic SQ109 for ethambutol in a mouse model of chronic tuberculosis (TB) improved efficacy of combination drug therapy with first-line TB drugs rifampin and isoniazid, with or without pyrazinamide: at 8 weeks, lung bacteria were 1.5 log 10 lower in SQ109-containing regimens.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.01326-06

Reference17 articles.

1. A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis

2. Bogatcheva, E., C. Hanrahan, B. Nikonenko, R. Samala, G. Gearhart, F. Barbosa, L. Einck, C. A. Nacy, and M. Protopopova. 2006. Identification of new diamine scaffolds with activity against Mycobacterium tuberculosis. J. Med. Chem.49:3045-3048.

3. Boshoff, H. I., T. G. Myers, B. R. Copp, M. R. McNeil, M. A. Wilson, and C. E. Barry III. 2004. The transcriptional responses of Mycobacterium tuberculosis to inhibitors of metabolism: novel insights into drug mechanisms of action. J. Biol. Chem.279:40174-40184.

4. Chen, P., G. Gearhart, M. Protopopova, L. Einck, and C. A. Nacy. 2006. Synergic interaction of SQ109, a new ethylene diamine, with front-line antitubercular drugs in vitro. J. Antimicrob. Chemother.58:332-337.

5. In Vitro and In Vivo Activities of Moxifloxacin and Clinafloxacin against Mycobacterium tuberculosis

Cited by 132 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CRISPR Interference-Mediated Silencing of the mmpL3 Gene in Mycobacterium smegmatis and Its Impact on Antimicrobial Susceptibility;Antibiotics;2024-05-24

2. Dominant negative biologics normalise the tumour necrosis factor (TNF-α) induced angiogenesis which exploits the Mycobacterium tuberculosis dissemination;BMC Immunology;2023-11-30

3. Recent advances in mycobacterial membrane protein large 3 inhibitor drug design for mycobacterial infections;Expert Opinion on Drug Discovery;2023-06-04

4. Perspective Chapter: Tuberculosis Drugs Doses from Indian Scenario – A Review;Dosage Forms - Innovation and Future Perspectives;2023-04-05

5. Structure-based design of anti-mycobacterial drug leads that target the mycolic acid transporter MmpL3;Structure;2022-10